Global Cleanroom Consumables Market By Product Type (Gloves, Wipes, Face Masks, Disposable Garments, Disinfectants, Goggles, Mops, Mats & Tapes, Paper, Others); By Sterility (Sterile, Non-sterile); By Distribution channel (Online, Offline); By End-use Industry (Healthcare, Aerospace and Defense, Automotive, Electronics/ Semiconductor, Food and Beverage, Others); By Material (PVC, Nitrile, Neoprene, Butyl, Vinyl, Latex, Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global cleanroom consumables market was valued at US$ 9,540.8 Mn in 2019 and is anticipated to grow at a CAGR of 7.6% to reach US$ 17,123.0 Mn in 2027 over the forecast period. The efficacies of cleanroom consumables to considerably reduce the contamination at workplace and improve quality products is propelling their demand in life science product manufacturing and other such industries.
When a company is involved in manufacturing of pharmaceuticals, chemicals, food and beverages or other products, controlling contamination is a vital aspect to maintain the quality of the products. Impurities if retained in the final product, pose a potential threat to end-use customers and can lead to mishaps. To maintain the quality of their product and beat the competition, companies are increasingly adopting cleanroom environments for performing manufacturing, research and development activities and final assembly of their products in a safe and controlled environment. According to International Organization for Standardization’s (ISO) definition a room which is specifically designed, constructed and operated in a manner to control the introduction, generation and retention of contaminant particles from air or humans or any products inside the room is called a cleanroom. The control of introduction, generation and retention of contaminant particles in a cleanroom is achieved through three ways: by supplying the room with a large quantity of air filtered with high efficiency filters, by making cleanroom itself with materials that do not generate contaminants and making the cleanroom operators wear garments that minimize dispersion of particles and micro-organisms generated by people’s hair, skin flakes, clothing fibers and others. Humans are the biggest sources of contamination in a cleanroom. Human base contamination accounts for 70% to 80% of cleanroom contamination. Using consumables and protective garments prevent microorganisms from reaching the cleanroom and is a relatively easy area to invest in compared with infrastructure changes. Thus, the efficiency of cleanroom garments to considerably reduce the particulate contamination from humans coupled with rising adoption of cleanroom technology in manufacturing companies is propelling the growth of cleanroom consumables market across the globe.
Cleanroom is witnessing tremendous transformations in terms of technologies. Advancements in cleanroom, environmental control and connectivity technologies are creating new cleanroom consumables offerings and also, opportunities for organisations to become increasingly efficient in their process. Cleanrooms Ltd provides a new range of modular cleanroom offerings which can suit to requirements of different industries. These new offerings are finding applications in newer industries thus, opening untapped revenue streams for cleanroom consumables manufacturers. Hence, the on-going advancements in cleanroom technology are propelling the growth of cleanroom consumables market, globally.
Growing penetration of counterfeit products in the market is hampering the growth of cleanroom consumables market. Counterfeit products have breached the supply chains of governmental agencies as wells as private businesses, thus, risking the contamination control in cleanrooms. To tackle the threat of counterfeit products, market players are adopting measures to make the original products identifiable with non-replicable labelling and tamperproof packaging. These factors are anticipated to arrest the penetration of illegal counterfeit products and boost the growth of global cleanroom consumables market over the forecast period.
By July 2020 rise in outbreak of global pandemic COVID-19 has affected more than 150 countries with more than 13.6 million cases. This pandemic has triggered number of research activities worldwide for developing effective vaccine to treat active COVID-19 patients. In April 2020, the Austrian Institute for Health Technology Assessment stated in press release that currently there are about 155 drugs and 79 vaccines for COVID-19 in development and trial phase. These research activities of drug development are performed in cleanroom environments to eliminate the influence of contaminants and obtain accurate results. The researchers, scientists, medical professionals among others are working round the clock in these cleanrooms leading to high demand for consumables including gloves, gowns, face masks, wipes and others. Thus, the high number of on-going drug and vaccine development activities amidst corona virus outbreak have positively impacted the demand for cleanroom consumables market across the globe.
Sterility Outlook:
The main function of the cleanroom consumables is to reduce contamination caused by particulates and microorganisms. This requirement poses sterile cleanroom consumables as highly preferred products over non-sterile products. Cleanroom consumable manufacturers can perform the sterility of their products at their facility or can outsource this activity to a third party vendor. This third party vendor is a dedicated company to laundry and sterility processes of cleanroom consumables. For instance, the STERIS company provides sterilization services for cleanroom consumables including disposable headwear, facemasks, clothing, wipes, petri-dish, environmental swabs and many others. These third party sterilization service providers offload the critical process from manufacturers thus enabling them to concentrate their resources on higher productivity thus increasing the global cleanroom consumables market.
End-Use Industry Outlook:
Based on the end-use industry, healthcare dominated the global cleanroom consumables market in 2018 owing to the large demand from pharmaceutical and biopharmaceutical companies for pharmaceutical fillings. In February 2019, Caldic B.V., a Belgian pharmaceutical company expanded its manufacturing capacity by adding a third cleanroom in at its site in Hemiksem, Belgium. Cleanroom is also used for the development of newer drugs. In 2018, the U.S Food and Drug Administration (USFDA) approved 59 new drugs as compared to 46 drugs approved in 2017. These numbers depict the rise in research and development activities of pharmaceutical companies. Also, the Pharma R&D Annual Review 2019 report states that there were around 16,000 drugs under development and trial phases in 2019 compared to 15,276 in 2018. These rise in research activities demand high use of cleanroom technology and consumables for quality control aspects thus, fuelling the share of healthcare industry in global cleanroom consumables market.
Regional Outlook:
North America region registered the highest share in global cleanroom consumables market in 2018. However the Asia Pacific region is anticipated to witness high growth rate owing to the growing pharmaceutical sector in the region which is the primary demand generator for cleanroom technologies and consumables. The Singapore Economic Development Board states that pharmaceutical market in Asia rose by 28% between 2012 and 2017 and is anticipated to grow by 42% from 2018 to 2022. Thus, growing pharmaceutical and biopharmaceutical industries in Asia Pacific region are anticipated to create high demand for cleanroom consumables hence propelling the share of this region in global cleanroom consumables market over forecast years. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Cleanroom Consumables Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of cleanroom consumables market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the cleanroom consumables market are AIRTECH JAPAN, Ltd., ANSELL LTD., Berkshire Corporation, CleanCon, Contec, Inc., DuPont, HANS J. MICHAEL GmbH, Helapet Ltd. (CliniMed Ltd.), Kimberly-Clark Worldwide, Inc., Maxons Technologies Ltd., MEDIVATORS Inc., Micronclean, Nitritex Ltd., SAKURAI CO., LTD, Shenzhen Selen Science & Technology Co., Ltd., Texwipe, Thermo Fisher Scientific and Veltek Associates, Inc. amongst others.
Global Cleanroom Consumables Market:
By Product Type
- Gloves
- Wipes
- Face Masks
- Disposable Garments
- Disinfectants
- Goggles
- Mops
- Mats & Tapes
- Paper
- Others
By Sterility
- Sterile
- Non-sterile
By Distribution channel
- Online
- Offline
By End-use Industry
- Healthcare
- Aerospace and Defense
- Automotive
- Electronics/ Semiconductor
- Food and Beverage
- Others
By Material
- PVC
- Nitrile
- Neoprene
- Butyl
- Vinyl
- Latex
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Dengue Drugs Market
6. Market Synopsis:
Dengue Drugs Market
7. Dengue Drugs Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Dengue Drugs Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Dengue Drugs Market
7.6. Porter’s
Five Force Analysis
8. Global Dengue Drugs Market Analysis and Forecasts, 2019 –
2027
8.1. Overview
8.1.1. Global
Dengue Drugs Market Revenue (US$ Mn)
8.2. Global
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
8.2.1. Hospitals
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Clinics
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Pharmacies
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Distribution
Channel
9. Global Dengue Drugs Market Analysis and Forecasts, 2019 –
2027
9.1. Overview
9.2. Global
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
9.2.1. Rx
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. OTC
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By Type
10. Global Dengue Drugs Market Analysis and Forecasts, 2019 –
2027
10.1. Overview
10.2. Global
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
10.2.1. Acetaminophen
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Rehydration
Therapy
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By Drug
Class
11. Global Dengue Drugs Market Analysis and Forecasts, 2019 –
2027
11.1. Overview
11.2. Global
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
11.2.1. Oral
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2018
11.2.1.3. Market
Forecast, 2019 – 2027
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2018
11.2.1.5.1.2. Market
Forecast, 2019 – 2027
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2018
11.2.1.5.2.2. Market
Forecast, 2019 – 2027
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2018
11.2.1.5.3.2. Market
Forecast, 2019 – 2027
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2018
11.2.1.5.4.2. Market
Forecast, 2019 – 2027
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2018
11.2.1.5.5.2. Market
Forecast, 2019 – 2027
11.2.2. Intravenous
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2018
11.2.2.3. Market
Forecast, 2019 – 2027
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2018
11.2.2.5.1.2. Market
Forecast, 2019 – 2027
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2018
11.2.2.5.2.2. Market
Forecast, 2019 – 2027
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2018
11.2.2.5.3.2. Market
Forecast, 2019 – 2027
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2018
11.2.2.5.4.2. Market
Forecast, 2019 – 2027
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2018
11.2.2.5.5.2. Market
Forecast, 2019 – 2027
11.3. Key
Segment for Channeling Investments
11.3.1. By
Route of Administration
12. North America Dengue Drugs Market Analysis and Forecasts,
2019 - 2027
12.1. Overview
12.1.1. North
America Dengue Drugs Market Revenue (US$ Mn)
12.2. North
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.2.1. Hospitals
12.2.2. Clinics
12.2.3. Pharmacies
12.2.4. Others
12.3. North
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.3.1. Rx
12.3.2. OTC
12.4. North
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.4.1. Acetaminophen
12.4.2. Rehydration
Therapy
12.4.3. Others
12.5. North
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.5.1. Oral
12.5.2. Intravenous
12.6. North
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.1.1.1. Hospitals
12.6.1.1.2. Clinics
12.6.1.1.3. Pharmacies
12.6.1.1.4. Others
12.6.1.2. U.S
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.2.1. Rx
12.6.1.2.2. OTC
12.6.1.3. U.S
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.1.3.1. Acetaminophen
12.6.1.3.2. Rehydration
Therapy
12.6.1.3.3. Others
12.6.1.4. U.S
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.1.4.1. Oral
12.6.1.4.2. Intravenous
12.6.2. Canada
12.6.2.1. Canada
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.2.1.1. Hospitals
12.6.2.1.2. Clinics
12.6.2.1.3. Pharmacies
12.6.2.1.4. Others
12.6.2.2. Canada
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.2.1. Rx
12.6.2.2.2. OTC
12.6.2.3. Canada
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.2.3.1. Acetaminophen
12.6.2.3.2. Rehydration
Therapy
12.6.2.3.3. Others
12.6.2.4. Canada
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.2.4.1. Oral
12.6.2.4.2. Intravenous
12.6.3. Mexico
12.6.3.1. Mexico
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.3.1.1. Hospitals
12.6.3.1.2. Clinics
12.6.3.1.3. Pharmacies
12.6.3.1.4. Others
12.6.3.2. Mexico
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.2.1. Rx
12.6.3.2.2. OTC
12.6.3.3. Mexico
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
12.6.3.3.1. Acetaminophen
12.6.3.3.2. Rehydration
Therapy
12.6.3.3.3. Others
12.6.3.4. Mexico
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.3.4.1. Oral
12.6.3.4.2. Intravenous
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.6.4.1.1. Hospitals
12.6.4.1.2. Clinics
12.6.4.1.3. Pharmacies
12.6.4.1.4. Others
12.6.4.2. Rest
of North America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
12.6.4.2.1. Rx
12.6.4.2.2. OTC
12.6.4.3. Rest
of North America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.6.4.3.1. Acetaminophen
12.6.4.3.2. Rehydration
Therapy
12.6.4.3.3. Others
12.6.4.4. Rest
of North America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.6.4.4.1. Oral
12.6.4.4.2. Intravenous
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Distribution Channel
12.7.3. By Type
12.7.4. By Drug
Class
12.7.5. By
Route of Administration
13. Europe Dengue Drugs Market Analysis and Forecasts, 2019 -
2027
13.1. Overview
13.1.1. Europe
Dengue Drugs Market Revenue (US$ Mn)
13.2. Europe
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.2.1. Hospitals
13.2.2. Clinics
13.2.3. Pharmacies
13.2.4. Others
13.3. Europe
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.3.1. Rx
13.3.2. OTC
13.4. Europe
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.4.1. Acetaminophen
13.4.2. Rehydration
Therapy
13.4.3. Others
13.5. Europe
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.1. Oral
13.5.2. Intravenous
13.6. Europe
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.1.1.1. Hospitals
13.6.1.1.2. Clinics
13.6.1.1.3. Pharmacies
13.6.1.1.4. Others
13.6.1.2. France
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.2.1. Rx
13.6.1.2.2. OTC
13.6.1.3. France
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.1.3.1. Acetaminophen
13.6.1.3.2. Rehydration
Therapy
13.6.1.3.3. Others
13.6.1.4. France
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.1.4.1. Oral
13.6.1.4.2. Intravenous
13.6.2. The UK
13.6.2.1. The
UK Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.2.1.1. Hospitals
13.6.2.1.2. Clinics
13.6.2.1.3. Pharmacies
13.6.2.1.4. Others
13.6.2.2. The
UK Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.2.1. Rx
13.6.2.2.2. OTC
13.6.2.3. The
UK Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.2.3.1. Acetaminophen
13.6.2.3.2. Rehydration
Therapy
13.6.2.3.3. Others
13.6.2.4. The
UK Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.2.4.1. Oral
13.6.2.4.2. Intravenous
13.6.3. Spain
13.6.3.1. Spain
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.3.1.1. Hospitals
13.6.3.1.2. Clinics
13.6.3.1.3. Pharmacies
13.6.3.1.4. Others
13.6.3.2. Spain
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.2.1. Rx
13.6.3.2.2. OTC
13.6.3.3. Spain
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.3.3.1. Acetaminophen
13.6.3.3.2. Rehydration
Therapy
13.6.3.3.3. Others
13.6.3.4. Spain
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.3.4.1. Oral
13.6.3.4.2. Intravenous
13.6.4. Germany
13.6.4.1. Germany
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.4.1.1. Hospitals
13.6.4.1.2. Clinics
13.6.4.1.3. Pharmacies
13.6.4.1.4. Others
13.6.4.2. Germany
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.2.1. Rx
13.6.4.2.2. OTC
13.6.4.3. Germany
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.4.3.1. Acetaminophen
13.6.4.3.2. Rehydration
Therapy
13.6.4.3.3. Others
13.6.4.4. Germany
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.4.4.1. Oral
13.6.4.4.2. Intravenous
13.6.5. Italy
13.6.5.1. Italy
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.5.1.1. Hospitals
13.6.5.1.2. Clinics
13.6.5.1.3. Pharmacies
13.6.5.1.4. Others
13.6.5.2. Italy
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.2.1. Rx
13.6.5.2.2. OTC
13.6.5.3. Italy
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.5.3.1. Acetaminophen
13.6.5.3.2. Rehydration
Therapy
13.6.5.3.3. Others
13.6.5.4. Italy
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.5.4.1. Oral
13.6.5.4.2. Intravenous
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.6.6.1.1. Hospitals
13.6.6.1.2. Clinics
13.6.6.1.3. Pharmacies
13.6.6.1.4. Others
13.6.6.2. Nordic
Countries Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.2.1. Rx
13.6.6.2.2. OTC
13.6.6.3. Nordic
Countries Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.6.3.1. Acetaminophen
13.6.6.3.2. Rehydration
Therapy
13.6.6.3.3. Others
13.6.6.4. Nordic
Countries Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.6.4.1. Oral
13.6.6.4.2. Intravenous
13.6.6.5. Nordic
Countries Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.6.7.1.1. Hospitals
13.6.7.1.2. Clinics
13.6.7.1.3. Pharmacies
13.6.7.1.4. Others
13.6.7.2. Benelux
Union Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.2.1. Rx
13.6.7.2.2. OTC
13.6.7.3. Benelux
Union Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.7.3.1. Acetaminophen
13.6.7.3.2. Rehydration
Therapy
13.6.7.3.3. Others
13.6.7.4. Benelux
Union Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.7.4.1. Oral
13.6.7.4.2. Intravenous
13.6.7.5. Benelux
Union Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.6.8.1.1. Hospitals
13.6.8.1.2. Clinics
13.6.8.1.3. Pharmacies
13.6.8.1.4. Others
13.6.8.2. Rest
of Europe Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.2.1. Rx
13.6.8.2.2. OTC
13.6.8.3. Rest
of Europe Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.6.8.3.1. Acetaminophen
13.6.8.3.2. Rehydration
Therapy
13.6.8.3.3. Others
13.6.8.4. Rest
of Europe Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.6.8.4.1. Oral
13.6.8.4.2. Intravenous
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Distribution Channel
13.7.3. By Type
13.7.4. By Drug
Class
13.7.5. By
Route of Administration
14. Asia Pacific Dengue Drugs Market Analysis and Forecasts, 2019
- 2027
14.1. Overview
14.1.1. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn)
14.2. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.2.1. Hospitals
14.2.2. Clinics
14.2.3. Pharmacies
14.2.4. Others
14.3. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.3.1. Rx
14.3.2. OTC
14.4. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.4.1. Acetaminophen
14.4.2. Rehydration
Therapy
14.4.3. Others
14.5. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.5.1. Oral
14.5.2. Intravenous
14.6. Asia
Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.1.1.1. Hospitals
14.6.1.1.2. Clinics
14.6.1.1.3. Pharmacies
14.6.1.1.4. Others
14.6.1.2. China
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.2.1. Rx
14.6.1.2.2. OTC
14.6.1.3. China
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.1.3.1. Acetaminophen
14.6.1.3.2. Rehydration
Therapy
14.6.1.3.3. Others
14.6.1.4. China
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.1.4.1. Oral
14.6.1.4.2. Intravenous
14.6.2. Japan
14.6.2.1. Japan
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.2.1.1. Hospitals
14.6.2.1.2. Clinics
14.6.2.1.3. Pharmacies
14.6.2.1.4. Others
14.6.2.2. Japan
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.2.1. Rx
14.6.2.2.2. OTC
14.6.2.3. Japan
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.2.3.1. Acetaminophen
14.6.2.3.2. Rehydration
Therapy
14.6.2.3.3. Others
14.6.2.4. Japan
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.2.4.1. Oral
14.6.2.4.2. Intravenous
14.6.3. India
14.6.3.1. India
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.3.1.1. Hospitals
14.6.3.1.2. Clinics
14.6.3.1.3. Pharmacies
14.6.3.1.4. Others
14.6.3.2. India
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.2.1. Rx
14.6.3.2.2. OTC
14.6.3.3. India
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.3.3.1. Acetaminophen
14.6.3.3.2. Rehydration
Therapy
14.6.3.3.3. Others
14.6.3.4. India
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.3.4.1. Oral
14.6.3.4.2. Intravenous
14.6.4. New
Zealand
14.6.4.1. New
Zealand Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.4.1.1. Hospitals
14.6.4.1.2. Clinics
14.6.4.1.3. Pharmacies
14.6.4.1.4. Others
14.6.4.2. New
Zealand Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.2.1. Rx
14.6.4.2.2. OTC
14.6.4.3. New
Zealand Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.4.3.1. Acetaminophen
14.6.4.3.2. Rehydration
Therapy
14.6.4.3.3. Others
14.6.4.4. New
Zealand Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.4.4.1. Oral
14.6.4.4.2. Intravenous
14.6.5. Australia
14.6.5.1. Australia
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.5.1.1. Hospitals
14.6.5.1.2. Clinics
14.6.5.1.3. Pharmacies
14.6.5.1.4. Others
14.6.5.2. Australia
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.2.1. Rx
14.6.5.2.2. OTC
14.6.5.3. Australia
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.5.3.1. Acetaminophen
14.6.5.3.2. Rehydration
Therapy
14.6.5.3.3. Others
14.6.5.4. Australia
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.5.4.1. Oral
14.6.5.4.2. Intravenous
14.6.6. South
Korea
14.6.6.1. South
Korea Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.6.1.1. Hospitals
14.6.6.1.2. Clinics
14.6.6.1.3. Pharmacies
14.6.6.1.4. Others
14.6.6.2. South
Korea Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.2.1. Rx
14.6.6.2.2. OTC
14.6.6.3. South
Korea Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.6.3.1. Acetaminophen
14.6.6.3.2. Rehydration
Therapy
14.6.6.3.3. Others
14.6.6.4. South
Korea Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.6.4.1. Oral
14.6.6.4.2. Intravenous
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.6.7.1.1. Hospitals
14.6.7.1.2. Clinics
14.6.7.1.3. Pharmacies
14.6.7.1.4. Others
14.6.7.2. Southeast
Asia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.2.1. Rx
14.6.7.2.2. OTC
14.6.7.3. Southeast
Asia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.6.7.3.1. Acetaminophen
14.6.7.3.2. Rehydration
Therapy
14.6.7.3.3. Others
14.6.7.4. Southeast
Asia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.7.4.1. Oral
14.6.7.4.2. Intravenous
14.6.7.5. Southeast
Asia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.6.8.1.1. Hospitals
14.6.8.1.2. Clinics
14.6.8.1.3. Pharmacies
14.6.8.1.4. Others
14.6.8.2. Rest
of Asia Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
14.6.8.2.1. Rx
14.6.8.2.2. OTC
14.6.8.3. Rest
of Asia Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.6.8.3.1. Acetaminophen
14.6.8.3.2. Rehydration
Therapy
14.6.8.3.3. Others
14.6.8.4. Rest
of Asia Pacific Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.6.8.4.1. Oral
14.6.8.4.2. Intravenous
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Distribution Channel
14.7.3. By Type
14.7.4. By Drug
Class
14.7.5. By
Route of Administration
15. Middle East and Africa Dengue Drugs Market Analysis and
Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn)
15.2. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.2.1. Hospitals
15.2.2. Clinics
15.2.3. Pharmacies
15.2.4. Others
15.3. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.3.1. Rx
15.3.2. OTC
15.4. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.4.1. Acetaminophen
15.4.2. Rehydration
Therapy
15.4.3. Others
15.5. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.5.1. Oral
15.5.2. Intravenous
15.6. Middle
East and Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.6.1.1.1. Hospitals
15.6.1.1.2. Clinics
15.6.1.1.3. Pharmacies
15.6.1.1.4. Others
15.6.1.2. Saudi
Arabia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.2.1. Rx
15.6.1.2.2. OTC
15.6.1.3. Saudi
Arabia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.1.3.1. Acetaminophen
15.6.1.3.2. Rehydration
Therapy
15.6.1.3.3. Others
15.6.1.4. Saudi
Arabia Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.6.1.4.1. Oral
15.6.1.4.2. Intravenous
15.6.2. UAE
15.6.2.1. UAE
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.2.1.1. Hospitals
15.6.2.1.2. Clinics
15.6.2.1.3. Pharmacies
15.6.2.1.4. Others
15.6.2.2. UAE
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.2.1. Rx
15.6.2.2.2. OTC
15.6.2.3. UAE
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.2.3.1. Acetaminophen
15.6.2.3.2. Rehydration
Therapy
15.6.2.3.3. Others
15.6.2.4. UAE
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.2.4.1. Oral
15.6.2.4.2. Intravenous
15.6.3. Egypt
15.6.3.1. Egypt
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.3.1.1. Hospitals
15.6.3.1.2. Clinics
15.6.3.1.3. Pharmacies
15.6.3.1.4. Others
15.6.3.2. Egypt
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.2.1. Rx
15.6.3.2.2. OTC
15.6.3.3. Egypt
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.3.3.1. Acetaminophen
15.6.3.3.2. Rehydration
Therapy
15.6.3.3.3. Others
15.6.3.4. Egypt
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.3.4.1. Oral
15.6.3.4.2. Intravenous
15.6.4. Kuwait
15.6.4.1. Kuwait
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.4.1.1. Hospitals
15.6.4.1.2. Clinics
15.6.4.1.3. Pharmacies
15.6.4.1.4. Others
15.6.4.2. Kuwait
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.2.1. Rx
15.6.4.2.2. OTC
15.6.4.3. Kuwait
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.4.3.1. Acetaminophen
15.6.4.3.2. Rehydration
Therapy
15.6.4.3.3. Others
15.6.4.4. Kuwait
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.4.4.1. Oral
15.6.4.4.2. Intravenous
15.6.5. South
Africa
15.6.5.1. South
Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.6.5.1.1. Hospitals
15.6.5.1.2. Clinics
15.6.5.1.3. Pharmacies
15.6.5.1.4. Others
15.6.5.2. South
Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.2.1. Rx
15.6.5.2.2. OTC
15.6.5.3. South
Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.6.5.3.1. Acetaminophen
15.6.5.3.2. Rehydration
Therapy
15.6.5.3.3. Others
15.6.5.4. South
Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.6.5.4.1. Oral
15.6.5.4.2. Intravenous
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.6.6.1.1. Hospitals
15.6.6.1.2. Clinics
15.6.6.1.3. Pharmacies
15.6.6.1.4. Others
15.6.6.2. Rest
of Middle East & Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts,
By Type
15.6.6.2.1. Rx
15.6.6.2.2. OTC
15.6.6.3. Rest
of Middle East & Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts,
By Drug Class
15.6.6.3.1. Acetaminophen
15.6.6.3.2. Rehydration
Therapy
15.6.6.3.3. Others
15.6.6.4. Rest
of Middle East & Africa Dengue Drugs Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.6.6.4.1. Oral
15.6.6.4.2. Intravenous
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Distribution Channel
15.7.3. By Type
15.7.4. By Drug
Class
15.7.5. By
Route of Administration
16. Latin America Dengue Drugs Market Analysis and Forecasts,
2019 - 2027
16.1. Overview
16.1.1. Latin
America Dengue Drugs Market Revenue (US$ Mn)
16.2. Latin
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
16.2.1. Hospitals
16.2.2. Clinics
16.2.3. Pharmacies
16.2.4. Others
16.3. Latin
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.3.1. Rx
16.3.2. OTC
16.4. Latin
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.4.1. Acetaminophen
16.4.2. Rehydration
Therapy
16.4.3. Others
16.5. Latin
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.5.1. Oral
16.5.2. Intravenous
16.6. Latin
America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.1.1.1. Hospitals
16.6.1.1.2. Clinics
16.6.1.1.3. Pharmacies
16.6.1.1.4. Others
16.6.1.2. Brazil
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.2.1. Rx
16.6.1.2.2. OTC
16.6.1.3. Brazil
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.6.1.3.1. Acetaminophen
16.6.1.3.2. Rehydration
Therapy
16.6.1.3.3. Others
16.6.1.4. Brazil
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.1.4.1. Oral
16.6.1.4.2. Intravenous
16.6.2. Argentina
16.6.2.1. Argentina
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.2.1.1. Hospitals
16.6.2.1.2. Clinics
16.6.2.1.3. Pharmacies
16.6.2.1.4. Others
16.6.2.2. Argentina
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.2.1. Rx
16.6.2.2.2. OTC
16.6.2.3. Argentina
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.6.2.3.1. Acetaminophen
16.6.2.3.2. Rehydration
Therapy
16.6.2.3.3. Others
16.6.2.4. Argentina
Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.2.4.1. Oral
16.6.2.4.2. Intravenous
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.6.3.1.1. Hospitals
16.6.3.1.2. Clinics
16.6.3.1.3. Pharmacies
16.6.3.1.4. Others
16.6.3.2. Rest
of Latin America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Type
16.6.3.2.1. Rx
16.6.3.2.2. OTC
16.6.3.3. Rest
of Latin America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.6.3.3.1. Acetaminophen
16.6.3.3.2. Rehydration
Therapy
16.6.3.3.3. Others
16.6.3.4. Rest
of Latin America Dengue Drugs Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.6.3.4.1. Oral
16.6.3.4.2. Intravenous
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Distribution Channel
16.7.3. By Type
16.7.4. By Drug
Class
16.7.5. By
Route of Administration
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2018
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. AbbVie
Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. ABIVAX
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. GSK group
of companies
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Johnson
& Johnson Services, Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Micro
Labs Ltd.
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Pfizer
Inc.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Sanofi
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Sun
Pharma
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Takeda
Pharmaceutical Company Limited
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Other
Research Companies
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
